TN2011000040A1 - Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists - Google Patents

Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists

Info

Publication number: TN2011000040A1
Authority: TN; Tunisia
Prior art keywords: receptor antagonists; crf; amide derivatives; cyclohexyl amide; cyclohexyl
Prior art date: 2008-08-07

Application number

TN2011000040A

Other languages

English (en)

Inventor

Anny-Odile Colson

Andrew James Culshaw

Lisa Rooney

Emily Stanley

Lilya Sviridenko

David Beattie

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-08-07

Filing date

2011-01-26

Publication date

2012-09-05

2011-01-26 Application filed by Novartis Ag filed Critical Novartis Ag

2012-09-05 Publication of TN2011000040A1 publication Critical patent/TN2011000040A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/79—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Otolaryngology (AREA)
Gynecology & Obstetrics (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Pregnancy & Childbirth (AREA)

TN2011000040A 2008-08-07 2011-01-26 Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists TN2011000040A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP08162006		2008-08-07
US20513909P	2009-01-14	2009-01-14
EP09150543		2009-01-14
PCT/EP2009/060150 WO2010015655A1 (fr)	2008-08-07	2009-08-05	Dérivés de cyclohexylamide et leur utilisation en tant qu'antagonistes des récepteurs de crf-1

Publications (1)

Publication Number	Publication Date
TN2011000040A1 true TN2011000040A1 (en)	2012-09-05

Family

ID=41653509

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000040A TN2011000040A1 (en)	2008-08-07	2011-01-26	Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists

Country Status (25)

Country	Link
US (3)	US8273900B2 (fr)
EP (1)	EP2323970B1 (fr)
JP (1)	JP5527745B2 (fr)
KR (1)	KR101302796B1 (fr)
CN (1)	CN102143940B (fr)
AR (1)	AR072969A1 (fr)
AU (1)	AU2009279089B2 (fr)
BR (1)	BRPI0917574A2 (fr)
CA (1)	CA2732887A1 (fr)
CO (1)	CO6351776A2 (fr)
EA (1)	EA020921B1 (fr)
EC (1)	ECSP11010814A (fr)
ES (1)	ES2582576T3 (fr)
HN (1)	HN2011000372A (fr)
IL (1)	IL210834A0 (fr)
MA (1)	MA32534B1 (fr)
MX (1)	MX2011001375A (fr)
MY (1)	MY151568A (fr)
PE (1)	PE20110237A1 (fr)
SV (1)	SV2011003832A (fr)
TN (1)	TN2011000040A1 (fr)
TW (1)	TW201011001A (fr)
UY (1)	UY32036A (fr)
WO (1)	WO2010015655A1 (fr)
ZA (1)	ZA201100513B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8273900B2 (en) *	2008-08-07	2012-09-25	Novartis Ag	Organic compounds
WO2011092293A2 (fr) *	2010-02-01	2011-08-04	Novartis Ag	Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
CN102753527B (zh) *	2010-02-02	2014-12-24	诺华股份有限公司	用作crf受体拮抗剂的环己基酰胺衍生物
RU2639876C2 (ru)	2010-03-30	2017-12-25	Версеон Корпорейшн	Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
WO2012088397A2 (fr)	2010-12-22	2012-06-28	The Salk Institute For Biological Studies	Peptides cycliques antagonistes de la corticolibérine
UY34094A (es)	2011-05-27	2013-01-03	Novartis Ag	Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EP2567959B1 (fr)	2011-09-12	2014-04-16	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
TW201348235A (zh)	2012-05-03	2013-12-01	Novartis Ag	作爲格瑞啉受體促效劑之３－螺環哌啶衍生物
US9814723B2 (en)	2013-02-23	2017-11-14	Lixin Zhang	Compositions and methods for prophylaxis and therapy for Meniere's disease
HK1214252A1 (zh) *	2013-03-15	2016-07-22	Verseon Corporation	作為凝血酶抑制劑的鹵代吡唑
NZ711064A (en)	2013-03-15	2019-06-28	Verseon Corp	Pyridone-substituted pyrazolyl compounds as serine protease inhibitors
EP3096756B1 (fr)	2014-01-21	2024-06-12	Neurocrine Biosciences, Inc.	Antagonistes du récepteur crf1 pour le traitement de l'hyperplasie adrénale congénitale
BR112016028255A2 (pt)	2014-06-06	2017-08-22	Flexus Biosciences Inc	agentes imunorreguladores
US10189810B2 (en)	2014-09-17	2019-01-29	Verseon Corporation	Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
UY36390A (es)	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
UY36391A (es)	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
BR112017008809A2 (pt)	2014-11-05	2017-12-19	Flexus Biosciences Inc	agentes imunorreguladores
AU2016224974B2 (en)	2015-02-27	2019-09-26	Verseon Corporation	Substituted pyrazole compounds as serine protease inhibitors
KR20250048143A (ko)	2017-07-31	2025-04-07	노파르티스 아게	코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
AU2018383675A1 (en)	2017-12-13	2020-07-09	Altos Labs, Inc.	Inhibitors of integrated stress response pathway
JP7357932B2 (ja) *	2018-04-09	2023-10-10	ラクオリア創薬株式会社	Ｃｒｈｒ２拮抗薬としての縮合環状尿素誘導体
BR112020023115A2 (pt)	2018-06-05	2021-02-02	Praxis Biotech LLC	inibidores da via integrada de resposta a tensão
WO2020115555A2 (fr)	2018-12-07	2020-06-11	Neurocrine Biosciences, Inc.	Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale
CN114466654A (zh)	2019-06-12	2022-05-10	普拉西斯生物技术有限责任公司	整合应激反应通路调节剂
BR112021024431A2 (pt) *	2019-06-12	2022-01-18	Praxis Biotech LLC	Inibidores da via de resposta ao estresse integrada
EP4034111A1 (fr)	2019-09-27	2022-08-03	Neurocrine Biosciences, Inc.	Antagonistes du récepteur crf et méthodes d'utilisation
EP4222142A4 (fr)	2020-09-30	2024-10-16	RaQualia Pharma Inc.	Dérivés de 3-hydroxyoxindole utiles en tant qu'antagonistes du crhr2

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2417216A1 (de)	1974-04-09	1975-11-06	Basf Ag	Fungizide
DE2828265A1 (de)	1978-06-28	1980-01-17	Bayer Ag	Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen acetaniliden
DE3600288A1 (de)	1986-01-08	1987-07-16	Bayer Ag	Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten
DE3618004A1 (de)	1986-05-28	1987-12-03	Bayer Ag	Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten
WO1990005723A1 (fr)	1988-11-24	1990-05-31	Yoshitomi Pharmaceutical Industries, Ltd.	Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine
JP2770497B2 (ja)	1988-11-24	1998-07-02	吉富製薬株式会社	トランス―４―アミノ（アルキル）―１―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途
JP2864489B2 (ja)	1991-02-27	1999-03-03	吉富製薬株式会社	喘息治療剤
DE4107571A1 (de)	1991-03-07	1992-11-19	Diagnostikforschung Inst	Amid-chelate, deren metallkomplexe sowie ihre verwendung in diagnostik und therapie
EP0524439A1 (fr)	1991-07-24	1993-01-27	F.Hoffmann-La Roche & Co. Aktiengesellschaft	Dérivés du cyclohexane et du tétrahydropyranne et compositions antifongiques contenant ces dérivés
KR940702451A (ko)	1991-09-06	1994-08-20	고야 다다시	4-아미로(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
WO1993011731A2 (fr)	1991-12-12	1993-06-24	The Trustees Of The University Of Pennsylvania	Peptidomimetisme alicyclique
JP3218356B2 (ja)	1993-03-31	2001-10-15	ヤンマー農機株式会社	管理機
JPH0841006A (ja)	1994-08-05	1996-02-13	Nisshin Flour Milling Co Ltd	ジウレア誘導体
US6107300A (en)	1996-03-27	2000-08-22	Dupont Pharmaceuticals	Arylamino fused pyrimidines
CA2257950A1 (fr)	1996-06-28	1998-01-08	Merck & Co., Inc.	Promedicaments antagonistes de recepteurs de fibrinogenes
SE9802206D0 (sv)	1998-06-22	1998-06-22	Astra Pharma Inc	Novel compounds
SE9802208D0 (sv)	1998-06-22	1998-06-22	Astra Pharma Inc	Novel compounds
AU5198199A (en)	1998-08-17	2000-03-06	Senju Pharmaceutical Co., Ltd.	Preventives/remedies for glaucoma
JP4531990B2 (ja)	1999-03-25	2010-08-25	田辺三菱製薬株式会社	間質性肺炎・肺線維症の予防・治療薬
WO2000064477A1 (fr)	1999-04-22	2000-11-02	Mitsubishi Pharma Corporation	Compositions preventives/ traitements contre l'angiostenose
CN100438910C (zh)	1999-04-27	2008-12-03	田边三菱制药株式会社	肝脏疾病的预防治疗药
US6291499B1 (en)	1999-10-29	2001-09-18	Merck & Co., Inc.	2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US20040038855A1 (en) *	1999-12-30	2004-02-26	Salon John A.	DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
GB0002100D0 (en)	2000-01-28	2000-03-22	Novartis Ag	Organic compounds
JP2003529560A (ja)	2000-01-28	2003-10-07	ナショナルユニバーシティオブシンガポール	新規リガンドおよび同一物を調製するための方法
US6344733B1 (en)	2000-01-31	2002-02-05	Snap-On Technologies, Inc.	Portable jump-starting battery pack with charge monitoring system
US6915807B2 (en)	2000-02-23	2005-07-12	Young Sik Choi	Hair setting device
AU2001234180A1 (en)	2000-02-25	2001-09-03	Japan Tobacco Inc.	Benzamide derivative and use thereof
JP4776138B2 (ja) *	2000-03-31	2011-09-21	田辺三菱製薬株式会社	腎臓疾患予防・治療剤
ATE465756T1 (de)	2000-06-23	2010-05-15	Mitsubishi Tanabe Pharma Corp	Antitumoreffekt-verstärker
AU2001270183A1 (en)	2000-06-27	2002-01-08	Genelabs Technologies, Inc.	Novel compounds possessing antibacterial, antifungal or antitumor activity
US6720324B2 (en) *	2000-07-05	2004-04-13	Synaptic Pharmaceutical Corporation	Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
BR0113408A (pt)	2000-08-16	2003-06-17	Hoffmann La Roche	Derivados de aminociclohexano
AU2002225767A1 (en)	2000-11-28	2002-06-11	Guilford Pharmaceuticals Inc.	Bisubstituted carbocyclic cyclophilin binding compounds and theirus
EP1217000A1 (fr)	2000-12-23	2002-06-26	Aventis Pharma Deutschland GmbH	Inhibiteurs du factor Xa et factor VIIa
US7109208B2 (en)	2001-04-11	2006-09-19	Senju Pharmaceutical Co., Ltd.	Visual function disorder improving agents
EP1403255A4 (fr)	2001-06-12	2005-04-06	Sumitomo Pharma	Inhibiteurs de rho kinase
US7544690B2 (en)	2001-10-01	2009-06-09	Taisho Pharmaceutical Co., Ltd.	MCH receptor antagonists
AU2002361846A1 (en)	2001-12-21	2003-07-15	Bayer Pharmaceuticals Corporation	Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2002364209A1 (en)	2001-12-26	2003-07-24	Genelabs Technologies, Inc.	Polyamide derivatives possessing antibacterial, antifungal or antitumor activity
WO2003082847A1 (fr)	2002-03-28	2003-10-09	Tanabe Seiyaku Co., Ltd.	Derive de benzofurane
WO2003104233A1 (fr)	2002-06-07	2003-12-18	Altana Pharma Ag	Derives de 4,5-dihydro-imidazo (4,5,1-ij) quinoline-6-ones et utilisation de ceux-ci en tant qu'inhibiteurs de la poly (adp-ribosyl) transferase (parp)
US20040072802A1 (en) *	2002-10-09	2004-04-15	Jingwu Duan	Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
BR0315845A (pt)	2002-11-21	2005-09-27	Pharmacia & Upjohn Co Llc	Compostos de pirazina como moduladores de crf
MXPA05005794A (es)	2002-12-02	2005-08-16	Hoffmann La Roche	Derivados de indazol como antagonistas del factor de liberacion de corticotropina.
US7589207B2 (en)	2002-12-13	2009-09-15	Smithkline Beecham Corporation	Cyclohexyl compounds as CCR5 antagonists
JP2004203748A (ja)	2002-12-24	2004-07-22	Kissei Pharmaceut Co Ltd	新規なイミダゾ［１，２−ｃ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
KR101076018B1 (ko)	2003-01-08	2011-10-21	유니버시티 오브 워싱톤	항균제
JP2004238296A (ja)	2003-02-04	2004-08-26	Kissei Pharmaceut Co Ltd	新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EP1464335A3 (fr)	2003-03-31	2007-05-09	Taisho Pharmaceutical Co. Ltd.	Derivés de quinolines, tetrahydroquinolines et pyrimidines comme antagonistes du MCH
JP2004315511A (ja)	2003-03-31	2004-11-11	Taisho Pharmaceut Co Ltd	Ｍｃｈ受容体アンタゴニスト
JP4273821B2 (ja)	2003-04-21	2009-06-03	ヤマハ株式会社	音声データ処理プログラム
CN100402495C (zh)	2003-09-22	2008-07-16	弗·哈夫曼-拉罗切有限公司	氨基烷基酰胺取代的环己基衍生物
JP4289264B2 (ja)	2003-09-26	2009-07-01	田辺三菱製薬株式会社	医薬組成物
GB0325956D0 (en)	2003-11-06	2003-12-10	Addex Pharmaceuticals Sa	Novel compounds
CN1906198A (zh) *	2003-11-25	2007-01-31	布里斯托尔-迈尔斯斯奎布药品公司	吡唑并[1,5－α]－1,3,5－三嗪和其中间物的制备方法
GB0403038D0 (en)	2004-02-11	2004-03-17	Novartis Ag	Organic compounds
CA2558915A1 (fr)	2004-03-30	2005-10-13	Taisho Pharmaceutical Co., Ltd.	Derives de pyrimidine et procedes de traitement lies a l'utilisation de ceux-ci
EP1758580A4 (fr)	2004-06-24	2008-01-16	Incyte Corp	Piperidines a substitution n et utilisation de ces dernieres en tant que substances pharmaceutiques
PL1775298T3 (pl)	2004-07-01	2013-08-30	Daiichi Sankyo Co Ltd	Pochodna tienopirazolowa wykazująca aktywność hamowania PDE7
JP2008505910A (ja)	2004-07-08	2008-02-28	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	Ｐｋｃ−シータのインヒビターとして有用なピリミジン誘導体
WO2006023844A2 (fr)	2004-08-20	2006-03-02	Entremed, Inc.	Compositions et procedes comportant des antagonistes de recepteur active par la proteinase
WO2006034341A2 (fr) *	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
JP2006124387A (ja)	2004-09-30	2006-05-18	Taisho Pharmaceut Co Ltd	新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
US20080090863A1 (en)	2004-09-30	2008-04-17	Taisho Pharmaceutical Co., Ltd.	Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
US7491720B2 (en) *	2004-10-29	2009-02-17	Banyu Pharmaceutical Co., Ltd.	Aminopyridine derivatives having Aurora A selective inhibitory action
EP1813609B1 (fr)	2004-10-29	2013-06-19	Msd K.K.	Nouveaux derives d'aminopyridine presentant un effet inhibiteur selectif d'aurora-a
WO2006057270A1 (fr)	2004-11-26	2006-06-01	Asahi Kasei Pharma Corporation	Composé tricyclique azoté
GB0510141D0 (en)	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B3
GB0510139D0 (en)	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B1
JP2007091649A (ja)	2005-09-29	2007-04-12	Taisho Pharmaceut Co Ltd	ピリミジン誘導体及びその使用に関連する治療方法
JPWO2007063839A1 (ja)	2005-11-30	2009-05-07	塩野義製薬株式会社	シクロヘキサン誘導体
DE102005061428A1 (de)	2005-12-22	2007-08-16	Grünenthal GmbH	Substituierte Cyclohexylmethyl-Derivate
JPWO2007083689A1 (ja)	2006-01-19	2009-06-11	株式会社レナサイエンス	プラスミノーゲンアクチベーターインヒビター−１阻害剤
JP2007291087A (ja)	2006-03-29	2007-11-08	Taisho Pharmaceut Co Ltd	ピリジン誘導体及びその使用に関連する治療法
TW200815351A (en)	2006-05-02	2008-04-01	Astrazeneca Ab	Novel compounds
AU2007265368A1 (en)	2006-06-29	2008-01-03	Alantos Pharmaceuticals Holding, Inc.	Metalloprotease inhibitors
MX2009004615A (es)	2006-10-31	2009-05-22	Hoffmann La Roche	Derivados de eter como moduladores duales de los receptores de 5-hidroxitriptamina a (5-ht2a) y dopamina (d3).
JP5205274B2 (ja)	2006-11-22	2013-06-05	日本農薬株式会社	新規なピラゾール誘導体、有害生物防除剤及びその使用方法
WO2008065500A2 (fr)	2006-11-30	2008-06-05	Pfizer Products Inc.	Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i
WO2008073670A2 (fr)	2006-12-08	2008-06-19	Millennium Pharmaceuticals, Inc.	Formulations de doses unitaires et procédés de traitement d'une thrombose avec un inhibiteur oral du facteur xa
US7795249B2 (en)	2006-12-22	2010-09-14	Millennium Pharmaceuticals, Inc.	Certain pyrazoline derivatives with kinase inhibitory activity
PE20081785A1 (es)	2007-02-19	2009-01-12	Novartis Ag	Derivados de ciclohexil-amida del acido aril carboxilico
WO2008124000A2 (fr)	2007-04-02	2008-10-16	Ligand Pharmaceuticals Incorporated	Dérivés de thiazole utilisés comme composés modulateurs de récepteurs d'androgènes
TWI519508B (zh)	2007-06-12	2016-02-01	Achaogen Inc	抗菌劑
US20090270452A1 (en)	2008-04-18	2009-10-29	Arete Therapeutics, Inc.	Use of soluble epoxide hydrolase inhibitors in the treatment of smooth muscle disorders
ES2552549T3 (es)	2008-04-23	2015-11-30	Rigel Pharmaceuticals, Inc.	Compuestos de carboxamida para el tratamiento de trastornos metabólicos
WO2009151800A1 (fr)	2008-05-07	2009-12-17	Merck & Co., Inc.	Inhibiteurs d’époxyde hydrolase solubles, compositions contenant de tels composés et procédés de traitement
AR071719A1 (es)	2008-05-13	2010-07-07	Boehringer Ingelheim Int	Derivados aliciclicos de acido carboxilico de benzomorfanos y estructuras relacionadas, medicamentos que contienen dichos compuestos y su uso.procesos de obtencion
KR20110014229A (ko)	2008-05-27	2011-02-10	더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템	Ｗｎｔ 단백질 신호전달 억제제
US20090298834A1 (en)	2008-06-02	2009-12-03	Hassan Pajouhesh	4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers
WO2009153720A1 (fr)	2008-06-18	2009-12-23	Pfizer Limited	Dérivés de nicotinamide
US7994203B2 (en)	2008-08-06	2011-08-09	Novartis Ag	Organic compounds
US8273900B2 (en)	2008-08-07	2012-09-25	Novartis Ag	Organic compounds
US20100063583A1 (en)	2008-08-29	2010-03-11	Arete Therapeutics, Inc.	Use of soluble epoxide hydrolase inhibitors in the treatment of inflammatory vascular diseases
WO2010048149A2 (fr)	2008-10-20	2010-04-29	Kalypsys, Inc.	Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
AU2009309019B2 (en)	2008-10-31	2014-11-13	Merck Sharp & Dohme Llc	P2X3, receptor antagonists for treatment of pain
WO2010085246A1 (fr)	2009-01-21	2010-07-29	Praecis Pharmaceuticals Inc	Dérivés de 2,4-diamino-1,3,5-triazine et de 4,6-diamino-pyrimidine et leur emploi en tant qu'inhibiteurs d'aggrécanase
US20120165309A1 (en)	2009-02-12	2012-06-28	Astellas Pharma Inc.	Hetero ring derivative

2009
- 2009-07-31 US US12/462,318 patent/US8273900B2/en not_active Expired - Fee Related
- 2009-08-05 CA CA2732887A patent/CA2732887A1/fr not_active Abandoned
- 2009-08-05 BR BRPI0917574A patent/BRPI0917574A2/pt not_active IP Right Cessation
- 2009-08-05 WO PCT/EP2009/060150 patent/WO2010015655A1/fr not_active Ceased
- 2009-08-05 MX MX2011001375A patent/MX2011001375A/es active IP Right Grant
- 2009-08-05 PE PE2011000132A patent/PE20110237A1/es not_active Application Discontinuation
- 2009-08-05 US US13/057,015 patent/US8614213B2/en active Active
- 2009-08-05 ES ES09804572.7T patent/ES2582576T3/es active Active
- 2009-08-05 EP EP09804572.7A patent/EP2323970B1/fr active Active
- 2009-08-05 AU AU2009279089A patent/AU2009279089B2/en not_active Ceased
- 2009-08-05 KR KR1020117005153A patent/KR101302796B1/ko not_active Expired - Fee Related
- 2009-08-05 UY UY0001032036A patent/UY32036A/es not_active Application Discontinuation
- 2009-08-05 AR ARP090102998A patent/AR072969A1/es unknown
- 2009-08-05 MY MYPI20110353 patent/MY151568A/en unknown
- 2009-08-05 CN CN200980134704.5A patent/CN102143940B/zh not_active Expired - Fee Related
- 2009-08-05 EA EA201100306A patent/EA020921B1/ru not_active IP Right Cessation
- 2009-08-05 JP JP2011521570A patent/JP5527745B2/ja not_active Expired - Fee Related
- 2009-08-06 TW TW098126599A patent/TW201011001A/zh unknown
2011
- 2011-01-20 ZA ZA2011/00513A patent/ZA201100513B/en unknown
- 2011-01-24 IL IL210834A patent/IL210834A0/en unknown
- 2011-01-26 TN TN2011000040A patent/TN2011000040A1/fr unknown
- 2011-02-01 MA MA33574A patent/MA32534B1/fr unknown
- 2011-02-01 CO CO11011426A patent/CO6351776A2/es not_active Application Discontinuation
- 2011-02-07 SV SV2011003832A patent/SV2011003832A/es not_active Application Discontinuation
- 2011-02-07 HN HN2011000372A patent/HN2011000372A/es unknown
- 2011-02-07 EC EC2011010814A patent/ECSP11010814A/es unknown
2013
- 2013-11-22 US US14/087,773 patent/US20140088105A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20110152261A1 (en)	2011-06-23
AR072969A1 (es)	2010-10-06
MA32534B1 (fr)	2011-08-01
CO6351776A2 (es)	2011-12-20
ECSP11010814A (es)	2011-03-31
ES2582576T3 (es)	2016-09-13
IL210834A0 (en)	2011-04-28
CA2732887A1 (fr)	2010-02-11
TW201011001A (en)	2010-03-16
CN102143940A (zh)	2011-08-03
CN102143940B (zh)	2014-04-16
EP2323970A1 (fr)	2011-05-25
US20140088105A1 (en)	2014-03-27
JP5527745B2 (ja)	2014-06-25
US8614213B2 (en)	2013-12-24
SV2011003832A (es)	2011-07-05
ZA201100513B (en)	2011-10-26
WO2010015655A1 (fr)	2010-02-11
US8273900B2 (en)	2012-09-25
UY32036A (es)	2010-03-26
US20100035898A1 (en)	2010-02-11
PE20110237A1 (es)	2011-05-12
JP2011529944A (ja)	2011-12-15
KR101302796B1 (ko)	2013-09-02
EA201100306A1 (ru)	2012-01-30
BRPI0917574A2 (pt)	2015-11-17
AU2009279089B2 (en)	2012-08-23
HN2011000372A (es)	2013-05-20
EP2323970B1 (fr)	2016-04-20
EA020921B1 (ru)	2015-02-27
MY151568A (en)	2014-06-13
AU2009279089A1 (en)	2010-02-11
KR20110038730A (ko)	2011-04-14
MX2011001375A (es)	2011-03-15

Publication	Publication Date	Title
MY151568A (en)	2014-06-13	Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists
WO2011092293A3 (fr)	2011-10-20	Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
MX2009004881A (es)	2009-05-21	Anticuerpos agonistas de trkb y usos de los mismos.
ATE496051T1 (de)	2011-02-15	Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
PL396375A1 (pl)	2012-04-23	Kompozycje obejmujące arylopirazol i/lub formamidynę, sposoby i zastosowania je obejmujące
MX2010005317A (es)	2010-06-02	Polipeptidos de insulina modificados y sus usos.
EA201170227A1 (ru)	2011-06-30	Имидазолкарбоксамиды
MX344166B (es)	2016-12-07	Leptina-polipeptidos modificados y sus usos.
DE602007004999D1 (de)	2010-04-08	1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
IL210773A0 (en)	2011-03-31	Neuropeptide-2 receptor (y-2r) agonists and uses thereof
IL212364A0 (en)	2011-06-30	Neuropeptide-2-receptor (y-2r) agonists and uses thereof
IL185726A0 (en)	2008-01-06	Benzimidazole derivative and use as angiotensin ii antagonist
IL207649A0 (en)	2010-12-30	Substituted (pyrazolylcarbonyl) imidazolidinones and their use
SG149831A1 (en)	2009-02-27	Benzimidazole derivatives
IN2012DN01379A (fr)	2015-06-05
IL209718A0 (en)	2011-02-28	Substituted 7-sulfanylmethyl, 7-sulfinylmethyl and 7-sulfonylmethyl indoles and use thereof
UA105771C2 (uk)	2014-06-25	Похідні циклогексиламіду та їх застосування як антагоністів рецептора crf-1
CL2012000355A1 (es)	2012-08-31	Compuestos derivados de 4-amino-butenamida; composicion farmaceutica; y uso en el tratamiento de la epoc.
CL2009000317A1 (es)	2010-02-26	Compuestos derivados de 3-alquil-piperazina sustituida; composicion farmaceutica; y su uso en el tratamiento de la depresion y ansiedad.
HK1155721A (en)	2012-05-25	Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists
ZA200709002B (en)	2009-01-28	Benzimidazole derivative and use as angiotensin II antagonist
AU320425S (en)	2008-07-25	Ratchet clip
UA29770U (ru)	2008-01-25	Применение мигрепина как вещества с противоболевыми свойствами
UA50734U (en)	2010-06-25	use of interleukin-1 (ARIL-1) receptor antagonist as agent of antiamnestic, anticonvulsant and anxyolitic action
AU320681S (en)	2008-08-12	An extension